Navigation Links
Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
Date:11/5/2013

BASKING RIDGE, N.J., Nov. 5, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Michael E. Mendelsohn, M.D., to the company's Board of Directors.  The appointment strengthens Regado's leadership team by infusing the Company with a world-renowned leader in cardiovascular research and clinical development as the Phase 3 REGULATE-PCI clinical trial is actively enrolling patients worldwide.

Dr. Mendelsohn brings to Regado an unparalleled combination of cardiovascular therapeutic expertise, large pharmaceutical company experience and academic achievement. Since June 2010, Dr. Mendelsohn has served as Senior Vice President and Global Franchise Head for Cardiovascular Diseases at Merck & Co.  While at Merck, he led research and development and global strategy for all cardiovascular programs from Discovery to Late Development. Prior to joining Merck in 2010, Dr. Mendelsohn spent 17 years at Tufts Medical Center, where he served as the first-ever Chief Scientific Officer and the Executive Director of the center's Molecular Cardiology Research Institute. Dr. Mendelsohn received his undergraduate degree in Chemistry and English from Amherst College and his M.D. from Harvard Medical School. He completed his residency in internal medicine and fellowship in cardiovascular medicine at the Brigham and Women's Hospital (BWH). From 1988 to 1993 Dr. Mendelsohn was a member of the faculty of the BWH Cardiology Division and an Assistant Professor of Medicine at Harvard Medical School. As a physician, scientist and international leader in molecular vascular biology, Dr. Mendelsohn has made major contributions to the field of molecul
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
2. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
3. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
4. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
6. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
7. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
8. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
9. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet ... use of special anti-vascular endothelial growth factor agents given by injection into the ... not have a scientific protocol for the many millions diagnosed with it. AMD ...
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... CHENGDU, China, Oct. 1, 2011 /PRNewswire-Asia-FirstCall/ -- ... or the "Company"), a pharmaceutical company that ... Chinese medicine, branded generics and active pharmaceutical ... of the manufacturing environmental assessment at its ...
... 2011 Life Technologies Corporation (NASDAQ: ... detailing key steps of the Ion PGM™ sequencer ... at the core of Ion semiconductor sequencing are now openly ... as well as scientists that are closely watching the growth ...
... , Troy, N.Y. Waste heat is a byproduct ... driving a car to flying an aircraft or operating ... have developed new nanomaterials that could lead to techniques ... work. The key ingredients for making marble-sized pellets of ...
Cached Biology Technology:JCM Receives the Approval for its Manufacturing Environmental Assessment 2Open Ion Community Fuels Race to Win Three $1M Prizes 2Open Ion Community Fuels Race to Win Three $1M Prizes 3Open Ion Community Fuels Race to Win Three $1M Prizes 4Open Ion Community Fuels Race to Win Three $1M Prizes 5Rensselaer engineers 'cook' promising new heat-harvesting nanomaterials in microwave oven 2
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... Germany , August 6, 2015 ... Instruments (SMI) shows the world,s first Eye ... on Epson,s Moverio BT-200 see-through head mounted display and ... solution, unprecedented quality and efficiency is brought to personalized ... For the first time, professionals and researchers can integrate ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... pathway that plays a critical role in the growth ... important insight into the development of the vascular system ... inhibiting the blood vessels that fuel cancers, diabetic eye ... published online on Oct. 14 in Nature Genetics. was ...
... 13, 2007Today at the Prostate Cancer Foundations Annual Scientific ... common foods such as tomatoes and fish, maintaining a ... may help prevent prostate cancer, and help men live ... men will be diagnosed with prostate cancer in their ...
... been awarded to the Intergov-ernmental Panel on Climate Change (IPCC) ... about man-made climate change, and to lay the foundations for ... In particular, the 4th United Nations Climate Report on global ... and May 2007 revealed new facts and has been a ...
Cached Biology News:Study reveals a key to blood vessel growth and possible drug target 2Study reveals a key to blood vessel growth and possible drug target 3Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3Nobel Peace Prize 2007 to intergovernmental panel on climate change 2
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
... The Model 175 tube gel cell is ... gels for 2-D electrophoresis applications. The upper ... OD tubes 9-23 cm long for isoelectric ... upper buffer chamber and cooling core, lower ...
Biology Products: